Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: TGTX

TG Therapeutics, Inc.

Healthcare | Biotechnology

No licensed closing price on file for TGTX. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$2.74

TG Therapeutics, Inc. (NASDAQ: TGTX) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 16:51 UTC.

What TG Therapeutics, Inc. does

TG Therapeutics is a biotechnology company that acquires, develops, and commercializes treatments for B-cell diseases. The company has received FDA approval for BRIUMVI, a monoclonal antibody administered as an infusion every 24 weeks to treat adults with relapsing forms of multiple sclerosis, and has commercialized it in the U.S. and several countries outside the U.S. through a partnership with Neuraxpharm.

Summarized from TG Therapeutics, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Key facts

Valuation
EPS (TTM)$2.74
Return on equity69.01%
Debt/equity1.23

Revenue, margins & earnings

FY2021: net loss $348M on revenue $7M$7MFY2021FY2022: net loss $224M on revenue $3M$3MFY2022FY2023 Net income: $13MFY2023 Taxes & interest: $8MFY2023 Operating costs: $213M$234MFY2023FY2024 Net income: $23MFY2024 Taxes & interest: $19MFY2024 Operating costs: $287M$329MFY2024FY2025 Revenue: $616M — margin split not shown (non-operating gains)$616MFY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-09-14
  • 2026-09-14DirectorSale-5,000$274.8K
  • 2026-08-07DirectorGift-450—
  • 2026-08-07DirectorGift-5,100—
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does TG Therapeutics, Inc. do?

TG Therapeutics is a biotechnology company that acquires, develops, and commercializes treatments for B-cell diseases.

When did TGTX last file with the SEC?

TG Therapeutics, Inc.'s most recent SEC filing on record is a 8-K filed 2026-06-12. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 16:51 UTC. This page is also available as JSON at /api/data?ticker=TGTX and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for TGTX and 5,000+ tickers.

Create a free account — keep TGTX
For your agent
GET /api/data?ticker=TGTX

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt